

Dry Eye Syndromes

The spectrum of dry eye disease (DED) varies from a mild, self-limiting, irritation to severe, sight-threatening disease. The quality of life impact of moderate DED compares to that of life on haemodialysis or with mild angina.

Triaging DED

Mild	Soreness, irritation, discomfort	Negligible impact on the vision	Temporary treatment 1-2 x day with OTC drops
Moderate	Increased discomfort	Transient blurring of vision	Long-term use of drops 4 or more times per day
Severe	Marked discomfort or pain	Reduction in vision	Use of drops every 1-2 hours

Dry Eye disease is classified into

- Evaporative Dry Eye Disease, where there is poor tear function, usually due to blepharitis or Meibomian Gland Dysfunction
- Aqueous Deficiency Dry Eye disease, where there is insufficient tear production

Short-term Treatment

As per NHS England Guidance² self-care with OTC medication should be encouraged for conditions that are 'self-limiting' or are a 'minor issue'.

Patients may ask for advice on which treatments to purchase. There is significant variety in the quality and value of Dry Eye Disease treatments available OTC. More expensive preservative-free treatments may afford better value for a patient as the bottle will last longer with a shelf-life up to 6 months rather than the usual 28 days for a preserved bottle. Patients requiring drops more than 3-4 times per day would be recommended to use preservative-free treatment.

- Thinner/less viscous drops (e.g. hypromellose or polyvinyl alcohol) will provide more temporary relief albeit with less blurring.
- Thicker/more viscous drops (e.g. carboxymethyl cellulose, hyaluronic acid) will cause longer term relief, but may cause blurring of vision.
- Ointments (e.g. VitaPos, Lacrilube) can be recommended for night-time use if the patient complains of symptoms at night-time or on waking.

Evaporative Dry Eye as a result of blepharitis or meibomian gland dysfunction is the most common form of dry eye disease in clinical practice.³ For these patients, the daily use of warm compress in particular with microwaveable 'bean bag' masks (e.g. EyeBag, Meibopatch) and the occasional use of lid wipes (eg. Optase, Blephaclean) is essential.

Long-term Treatment

NHS England Guidelines state that patients should continue to have treatments prescribed if the condition is 'long-term', more complex, 'not minor', 'complex', POM, not responded to OTC or patients who are not capable of self-care.

Preservative-free treatment

'Ideally' all treatment would be preservative free⁴, as all preservatives cause damage to the ocular surface. Nevertheless, there is generally a higher cost with preservative-free preparations. Preservative-free medication is to be considered if the patient is intolerant/allergic to preservatives, if the treatment is likely to be prolonged or if the patient requires more than 4 drops/day especially if the patient has severe symptoms or if associated with a systemic disease (e.g. Sjögren's syndrome).

Advice for patients on administering eye drops: www.myeyedrops.info

Approved by One Gloucestershire Medicines Optimisation Group Review date: July 2022

Page 1 of 2

¹ Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006 Jul;4(3):155-61

² https://www.england.nhs.uk/publication/conditions-for-which-over-the-counter-items-should-not-routinely-be-prescribed-in-primary-careguidance-for-ccgs/

TFOS DEWS II Epidemiology Report Ocul Surf. 2017 Jul;15(3):334-365.

⁴ TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017 Jul;15(3):575-628.



Recommended Treatments for patients with Moderate to Severe Dry Eye Disease

Patients with mild DED should be directed to self-care with OTC medication. The following treatments are suggested for moderate and severe DED only.

Referral to a Corneal Specialist should be considered if the patient has continuing clinical signs or symptoms, despite using regular topical lubricants, or if there are other features that might suggest a systemic cause, such as *oral dryness* or enlarged salivary glands.

Eye Drops

Product	Active ingredient(s)	Unit Price*	Comments
Evolve HA®	Sodium hyaluronate 0.2%	£5.99 (10ml)	
Clinitas Multi®	Sodium hyaluronate 0.4%	£6.99 (10ml)	
Thealoz Duo®	Sodium hyaluronate 0.15%, treahalose 3%	£8.99 (10ml)	
Systane Balance®	Propylene glycol 0.6%	£7.49 (10ml)	In Evaporative Dry Eye Disease with blepharitis/meibomian Gland Dysfunction
VisuXL®	Sodium hyaluronate 0.1%, co-enzyme Q10 0.1%, vitamin E 0.5%	£10.30 (10ml)	If Chronic Keratitis
llube®	Acetylcysteine 5%, hypromellose 0.35%	£33.46 (10ml)	If Filamentary Keratitis Specialist initiation only

Eye Ointments

Product	Ingredient(s)	Unit Price*	Comments
Hydramed Night®	Retinol palmitate 250iu/g, liquid paraffin, white soft paraffin, wool fat	£2.32 (5g)	
Xailin Night®	White soft paraffin, white mineral oil, lanolin alcohols	£2.54 (5g)	
Hydramed Night Sensitive®	Retinol palmitate 250iu/g, liquid paraffin, white soft paraffin (lanolin free)	£8.34 (5g)	Patients with lanolin allergy

Anti-Inflammatory Treatments

For patients, <u>under secondary care</u>, *with persistent clinical signs despite intensive lubricant treatment*, local anti-inflammatory should be considered.

Product	Active ingredient(s)	Cost per Dose*	Comments
Softacort®	Hydrocortisone 0.3%	£0.37 Single Unit Dose	Specialist initiation only
Prednisolone minims®	Prednisolone 0.5%	£0.61 Single Unit Dose	Specialist initiation only
lkervis®	Ciclosporin 0.1%	£2.40 Single Unit Dose	Specialist prescribing only

*Prices MIMS March 2020